LONDON (Thomson Financial) - Pliva D D said its pretax profit for the for the nine months ended Sept 30 rose by 211.9 pct boosted by the transfer of ownership of its US business and the divestment of some non-core operations.
The company, which is Barr Pharmaceuticals Inc's European generic pharmaceutical subsidiary, said its pretax profit jumped to 1.1 bln Croatian kuna from 358 mln a year ago, as total revenues increased to 4.9 bln kuna from 4.6 bln.
Pliva's total sales declined to 4.03 bln Croatian kuna from 4.35 bln due to significantly lower Pharma Chemicals sales and the loss of US customer sales in its reporting results, on account of the US business transfer. TFN.newsdesk@thomson.com yos/faj/ajb COPYRIGHT Copyright Thomson Financial News Limited 2007. All rights reserved. The copying, republication or redistribution of Thomson Financial News Content, including by framing or similar means, is expressly prohibited without the prior written consent of Thomson Financial News.
© 2007 AFX News